However, an exploratory analysis of a pre-specified subgroup of patients with TP53 wild-type endometrial cancer showed a promising efficacy signal. In the SIENDO study, 263 patients were randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results